Session » Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Biomarkers

Date: Sunday, November 12, 2023

Time: 4:00PM-5:30PM

Meeting: ACR Convergence 2023

4:00PM-5:30PM: Abstract Number: 0847

Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0851

Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms

4:00PM-5:30PM: Abstract Number: 0849

Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0848

Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients

4:00PM-5:30PM: Abstract Number: 0850

Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis

4:00PM-5:30PM: Abstract Number: 0852

Screening for Specific Antinuclear Antibodies Using an Artificial Intelligence-enabled Antinuclear Antibody HEp-2 Substrate by Indirect Immunofluorescence Assay

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].